| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| Gene symbol | CD274 | Synonyms | B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1 | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9p24.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD274 molecule | ||||
| GTO ID | GTC2462 |
| Trial ID | NCT04556669 |
| Disease | Cervical Cancer | Sarcoma | Lung Non-Small Cell Carcinoma |
| Altered gene | CD22|PDL1 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell|CAR-TILs cell |
| Treatment | SL22P CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors |
| Year | 2020 |
| Country | China |
| Company sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Other ID(s) | Senl_C22P CAR-T/CAR-TIL |
| Cohort 1 | |||||||||
|
|||||||||